MedTrace Logo

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)

NCT00429923 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2009-07-02

Study results available
· View outcomes & findings →

Summary

The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.

Conditions

Interventions

DRUG

Difluprednate

DRUG

Difluprednate

DRUG

Placebo

Sponsors & Collaborators

  • Sirion Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Roger Vogel, MD · Sirion Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00429923 on ClinicalTrials.gov